These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23862154)

  • 1. A history of the development of Brucella vaccines.
    Avila-Calderón ED; Lopez-Merino A; Sriranganathan N; Boyle SM; Contreras-Rodríguez A
    Biomed Res Int; 2013; 2013():743509. PubMed ID: 23862154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The advances in brucellosis vaccines.
    Hou H; Liu X; Peng Q
    Vaccine; 2019 Jul; 37(30):3981-3988. PubMed ID: 31176541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research progress in live attenuated Brucella vaccine development.
    Wang Z; Wu Q
    Curr Pharm Biotechnol; 2013; 14(10):887-96. PubMed ID: 24372253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a Brucella vaccine for humans.
    Perkins SD; Smither SJ; Atkins HS
    FEMS Microbiol Rev; 2010 May; 34(3):379-94. PubMed ID: 20180858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease.
    Martins Rda C; Irache JM; Gamazo C
    Expert Rev Vaccines; 2012 Jan; 11(1):87-95. PubMed ID: 22149711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenic and protective antigens of Brucella as vaccine candidates.
    Masjedian Jezi F; Razavi S; Mirnejad R; Zamani K
    Comp Immunol Microbiol Infect Dis; 2019 Aug; 65():29-36. PubMed ID: 31300122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brucellosis vaccines for livestock.
    Goodwin ZI; Pascual DW
    Vet Immunol Immunopathol; 2016 Nov; 181():51-58. PubMed ID: 27032465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Human vaccination against brucellosis (Charles Nicolle)].
    Roux J
    Bull Acad Natl Med; 1986 Feb; 170(2):289-92. PubMed ID: 3527369
    [No Abstract]   [Full Text] [Related]  

  • 9. Brucellosis vaccines based on the open reading frames from genomic island 3 of Brucella abortus.
    Gómez L; Alvarez F; Betancur D; Oñate A
    Vaccine; 2018 May; 36(21):2928-2936. PubMed ID: 29685597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brucellosis: Improved Diagnostics and Vaccine Insights from Synthetic Glycans.
    Bundle DR; McGiven J
    Acc Chem Res; 2017 Dec; 50(12):2958-2967. PubMed ID: 29219305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipopolysaccharide as a target for brucellosis vaccine design.
    Conde-Álvarez R; Arce-Gorvel V; Gil-Ramírez Y; Iriarte M; Grilló MJ; Gorvel JP; Moriyón I
    Microb Pathog; 2013 May; 58():29-34. PubMed ID: 23219811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates.
    Todd TE; Tibi O; Lin Y; Sayers S; Bronner DN; Xiang Z; He Y
    BMC Bioinformatics; 2013; 14 Suppl 6(Suppl 6):S3. PubMed ID: 23735014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challenge.
    Moustafa D; Garg VK; Jain N; Sriranganathan N; Vemulapalli R
    Vaccine; 2011 Jan; 29(4):784-94. PubMed ID: 21109033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice.
    Jain-Gupta N; Contreras-Rodriguez A; Vemulapalli R; Witonsky SG; Boyle SM; Sriranganathan N
    FEMS Immunol Med Microbiol; 2012 Dec; 66(3):436-44. PubMed ID: 23163875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection.
    Ghasemi A; Jeddi-Tehrani M; Mautner J; Salari MH; Zarnani AH
    Vaccine; 2014 Nov; 32(49):6659-66. PubMed ID: 25240754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel drug targets for humans and potential vaccine targets for cattle by subtractive genomic analysis of Brucella abortus strain 2308.
    Mahmud A; Khan MT; Iqbal A
    Microb Pathog; 2019 Dec; 137():103731. PubMed ID: 31509762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-expression of homologous antigens in a leucine auxotroph of Brucella abortus strain RB51 protects mice against a virulent B. suis challenge.
    Rajasekaran P; Surendran N; Seleem MN; Sriranganathan N; Schurig GG; Boyle SM
    Vaccine; 2011 Apr; 29(17):3106-10. PubMed ID: 21376799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-infectious outer membrane vesicles derived from Brucella abortus S19Δper as an alternative acellular vaccine protects mice against virulent challenge.
    Solanki KS; Varshney R; Qureshi S; Thomas P; Singh R; Agrawal A; Chaudhuri P
    Int Immunopharmacol; 2021 Jan; 90():107148. PubMed ID: 33189614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
    Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
    Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.
    Arenas-Gamboa AM; Rice-Ficht AC; Kahl-McDonagh MM; Ficht TA
    Infect Immun; 2011 Sep; 79(9):3653-8. PubMed ID: 21708998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.